Recent Development in NSCLC Immunotherapies: Mechanisms, Advantages and Research Findings
DOI:
https://doi.org/10.62051/drgng326Keywords:
NSCLC; clinical treatment; Immunotherapies.Abstract
The NSCLC is a severe and common chronic disease in the whole world, and it has high mortality, which threatens human life. Therefore, the treatment of NSCLC is a hot topic in both society and the medical field. Nowadays, the treatment of NSCLC has many choices, for example, chemotherapeutic agents and radiotherapy drug treatments, these treatments of NSCLC are limited and have a lot of side effects to the patients, like unavoidable vomiting, hair loss, etc. The immunotherapist is the latest cancer treatment and it can improve curative effects and reduce adverse reactions. This article is based on the mechanism of NSCLC incidence and development and discusses the immunotherapies of NSCLC including the monoclonal antibody, immunity checkpoint inhibitors, and tumor therapeutic vaccines. It talks about the mechanisms of these treatments and the recent research findings of these treatments. It can provide references to the NSCLC clinical treatment and the clinical application of immunotherapies fields. This article also mentions the limitations and the challenges of tumor therapeutic vaccines, which can inspire researchers to find solutions and the progress of relevant limitations and challenges.
Downloads
References
[1] Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today [EB/OL]. Lyon, France: International Agency for Research on Cancer, 2024[2025-03-24]. Available from: https://gco.iarc.who.int/today.
[2] Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J, Colombet M, Bray F. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study [J]. Lancet Respir Med, 2025, Feb 3: S2213-2600(24)00428-4. DOI: https://doi.org/10.1016/S2213-2600(24)00428-4
[3] Hui R, Özgüroğlu M, Villegas A, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomized, controlled, phase 3 study [J]. The Lancet Oncology, 2019, 20(12). DOI: https://doi.org/10.1016/S1470-2045(19)30519-4
[4] Zou K, Sun P, Huang H, et al. Etiology of lung cancer: Evidence from epidemiologic studies [J]. J Natl Cancer Cent, 2022, 2(4):216-225. DOI: https://doi.org/10.1016/j.jncc.2022.09.004
[5] World Health Organization. Lung cancer [EB/OL]. 2023-06-26[2025-03-17]. Available from: https://www.who.int/news-room/fact-sheets/detail/lung-cancer.
[6] Delbari P, Ahmadvand MH, Mirjani MS, et al. The safety and efficacy of anti-PD-1/PD-L1 monoclonal antibodies for lung cancer brain metastasis: a systematic review and meta-analysis on brain metastasis [J]. Neurosurg Rev, 2025, 48(1):253. DOI: https://doi.org/10.1007/s10143-025-03418-z
[7] Du XJ, Ma RY, Ren DW, Liu Q, Yan P. Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study [J]. Lung Cancer (Auckl), 2024, 15:29-40. DOI: https://doi.org/10.2147/LCTT.S444884
[8] Xu M, Hao Y, Zeng X, Si J, Song Z. Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer [J]. J Thorac Dis, 2023, 15(4):1648-1657. DOI: https://doi.org/10.21037/jtd-22-1611
[9] Tao Y, Tian C, Qi S, et al. Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors [J]. Nat Cancer, 2025. DOI: https://doi.org/10.1038/s43018-025-00930-5
[10] Abushanab AK, Mustafa MT, Mousa MT, et al. Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels [J]. Expert Rev Anticancer Ther, 2025, 25(2):167-179. doi:10.1080/14737140.2025.2460537. DOI: https://doi.org/10.1080/14737140.2025.2460537
[11] Liu J, Feng C, Zhao R, et al. GP73 reinforces cytotoxic T-cell function by regulating HIF-1α and increasing antitumor efficacy [J]. Journal for ImmunoTherapy of Cancer, 2025, 13: e009265. DOI: https://doi.org/10.1136/jitc-2024-009265
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
